Skip to main content

Table 1 Baseline characteristics and survival analysis of HCC patients treated with regorafenib

From: Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center

At the start of regorafenib

n/n

Kaplan–Meier

Multivariate Cox

mOS

P

RR (95%CI)

P

Gender (Male/Female)

81/12

15.9/12.2

0.686

  

Age (≤ 60/ > 60 years)

60/33

18.3/15.4

0.495

  

Alcoholism (No/Yes)

59/34

15.7/15.9

0.945

  

Hypertension (No/Yes)

72/21

16.9/12.2

0.877

  

Diabetes (No/Yes)

80/13

15.9/15.4

0.995

  

Portal hypertension(No/Yes)

64/29

15.7/16.9

0.603

  

HBV infection (No/Yes)

6/87

8.0/16.9

0.077

  

Child–Pugh (A/B)

85/8

16.9/7.3

0.032

2.802 (1.136–6.914)

0.025

Blood lymphocyte (≥ 1.0/ < 1.0 × 109/L)

52/41

19.8/14.2

0.130

  

NLR (< 2.5/ ≥ 2.5)

37/56

22.8/12.7

0.002

1.981 (1.105–3.551)

0.022

ALB (< 35/ ≥ 35 g/L)

12/81

11.6/15.9

0.098

  

TBil (< 17.1/ ≥ 17.1 µmol/L)

50/43

15.1/16.9

0.498

  

GGT (≤ 60/ > 60U/L)

53/40

21.2/14.1

0.070

  

ECOG PS (≤ 1/2)

73/20

20.5/8.0

< 0.001

3.016 (1.664–5.469)

 < 0.001

AFP (< 400/ ≥ 400 ng/mL)

62/31

15.9/15.1

0.916

  

BCLC stage (B/C)

29/64

22.1/15.2

0.105

  

Vascular invasion by naked eye (No/Yes)

86/7

16.9/12.2

0.510

  

Extrahepatic metastasis (No/Yes)

30/63

16.8/15.2

0.064

  

Pre-treatment (within 2 months, Yes/No)

48/45

19.7/15.2

0.744

  

Adverse events (0–1/ ≥ 2 grade)

49/44

20.5/14.5

0.220

  

Proteinuria (No/Yes)

64/29

15.9/15.4

0.893

  

Combination therapy (No/Yes)

33/60

11.6/19.8

0.012

0.522 (0.305–0.891)

0.017

At the first diagnosis of HCC

BCLC stage (A/B-C)

43/50

18.3/15.1

0.648

  

Vascular invasion (No/Yes)

79/14

18.3/8.7

0.068

  

Microvascular invasion (No/Yes)

28/47/18

22.1/14.2

0.060

  

Treatment (LT/hepatectomy/RFA)

17/63/13

22.8/15.9/15.4

0.898

  

Time from first diagnosis to regorafenib (> 24 months/ ≤ 24 months)

46/47

14.2/22.1

0.024

0.463 (0.260–0.824)

0.009

First-line systemic therapy (Sorafenib/others)

86/7

16.9/15.7

0.387

  

Time from first line to regorafenib (≤ 6.0 months/ > 6.0 months)

36/57

19.8/14.5

0.319

  
  1. HBV hepatitis B virus, NLR neutrophil-to-lymphocyte ratio, ALB albumin, TBil total bilirubin, GGT γ-Glutamyl transferase, ECOG PS Eastern Cooperative Oncology Group performance status, AFP Alpha-fetoprotein, BCLC Barcelona Clinic Liver Cancer
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us